Skip To Main Content
Ying Cheng on Muck Rack

Ying Cheng

As seen in: Arthritis & Rheumatology, Color Research & Application, Nature, Wiley, Wiley Online Library, PLOS ONE, Frontiers, Frontiers in Public Health, MDPI, Taylor & Francis Online and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying

Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial

|
By Jiayu Wang, Quchang Ouyang, Weimin Xie, Zhaofeng Niu, Qingyuan Zhang, Jianying Chang, Ying Cheng, Airong Wang, Jingfen Wang, Herui Yao, Tao Lin Sun, Zhongsheng Tong, Xinhong Wu, Yongsheng Wang, Enxiang Zhou, Xiangshun Kong, De Zeng, Shanshan Gu, Yanyan Hou, Dandan Gao, Jianmin Fang, Binghe Xu, Yue’e Teng, Zhuangqing Yang, Xujuan Wang, Zerui Qu, Chenran Han
| Nature Verified
Abstract Patients with HER2-positive advanced breast cancer with liver metastases (BCLM) have poor prognosis. Study RC48-C006 is a prospective, open-label, multi-center, randomized phase 2/3 trial (ClinicalTrials.gov identifier, NCT03500380). Based on the phase 2 results, the phase 3 stage was initiated to evaluate disitamab vedotin (DV) versus lapatinib plus capecitabine (L + C) in patients with HER2-positive BCLM who were previously treated with trastuzumab and taxanes.
Open in Who Shared Issue with article?

Empowerment model construction and empirical study of community-based recruitment of platelet donors

|
By Pei Yang, Xu Wan, Ying Cheng, Chunyan Yang, Danfeng Cheng, Yangyaqi Shao
| Frontiers in Public Health Verified
Abstract Objective: To address the structural mismatch between high clinical demand and limited public participation in platelet donation recruitment in megacities, this study constructed a three-dimensional community empowerment model—organizational empowerment, cognitive empowerment, and service empowerment—based on social capital theory, community governance theory, and planned behavior theory.
Open in Who Shared Issue with article?

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer : Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

|
By Jingjing Liu, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, HAOYU YU, Jing Li, Xinyi Yang, Qingyu Wang, Jun Zhu, Ahmet Bilici, Aihong Zhong, Alexandre Tavartkiladze, Bangwei Cao, Chun Liang Chen, Davit Giorgadze, Denys Pominchuk, Devrim Cabuk, Dongji Chen, Fedor Moiseenko, Feng Luo, Gaofeng Li, Gongyan Chen, Guangyu An, Guoping Sun, Guosheng Feng, Yanrong Song, Haixin Huang, Hakan Harputluoglu, Hao Xiong, Hui Zhao, Igor Bondarenko, Irfan Cicin, Ivan Sinelnikov, Jian Fang, Jiuwei Cui, Junguo Lu, Kejing Ying, Konstantin Penkov, Liqin Lu, Liyan Jiang, Lu Yue, Mahmut Gümüş, Mehmet Artaç, Mengzhao Wang, Min Fan, Mustafa Özgüroğlu, Peiguo Cao, Peiyan Zhao, Ping Sun, Robert M. Mróz, Sergey Orlov, Shuang Zhang, Shuqun Zhang, Tao Zhang, Tuncay Göksel, Wen Lin, Wenlei Zhuo, Xiaoli Zhu, Xiubao Ren, Yan Wang, Yanping Hu, Yarong Li, Ying Cheng, Yuksel Urun, Zhendong Chen, Zhenyu You, Zhixiong Yang, Zhong Lin, Zhuang Yu, Alev Türker, Amiran Matitashvili, Andrey Akopov, Andrii Gardashnikov, Cagatay Arslan, Eugeny Kulikov, Igor Lifirenko, Ligong Nie, Malgorzata Ulanska, Maria Smagina, Mariam Zhvania, Nadezhda Kovalenko, Oleg Kobziev, Oleksii Kolesnik, Olexandr Goloborodko, Sergey Cheporov, Shenpeng Ying, Tariel Kitiashvili, Timur Andabekov, Tsira Kortua, Vadim Shirinkin, Vladimer Kuchava, Yevhen Hotko, Yuriy Semegen
| JAMA Oncology Verified
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial Key Points Question What are the long-term efficacy and safety outcomes of adding serplulimab to first-line chemotherapy for previously untreated extensive-stage small cell lung cancer (ES-SCLC)?
Open in Who Shared Issue with article?
See all 155 licensed articles (161 Total)